![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
C-SWIFT Retreatment (Part B): 12 Weeks of
Elbasvir/Grazoprevir with Sofosbuvir and Ribavirin Successfully Treated G1-Infected Subjects who Failed Short-Duration All-Oral Therapy
|
|
|
Reported by Jules Levin
AASLD 2015 Nov 13-17 San Francisco
Eric Lawitz1; Fred Poordad1; Julio A. Gutierrez1; Jennifer T. Wells1;
Carmen E. Landaverde1; Joseph R. Reiling2; Jerry J. Li2; Hsueh-Cheng Huang2;
Michael Robertson2; Janice Wahl2; Eliav Barr2; Barbara A. Haber2
1Texas Liver Institute, San Antonio, TX, USA; 2Merck & Co., Inc., Kenilworth, NJ, USA
![AASLD1.gif](../images/112315/112315-1/AASLD1.gif)
![AASLD2.gif](../images/112315/112315-1/AASLD2.gif)
![AASLD3.gif](../images/112315/112315-1/AASLD3.gif)
![AASLD4.gif](../images/112315/112315-1/AASLD4.gif)
![AASLD5.gif](../images/112315/112315-1/AASLD5.gif)
![AASLD6.gif](../images/112315/112315-1/AASLD6.gif)
![AASLD7.gif](../images/112315/112315-1/AASLD7.gif)
![AASLD8.gif](../images/112315/112315-1/AASLD8.gif)
![AASLD9.gif](../images/112315/112315-1/AASLD9.gif)
![AASLD10.gif](../images/112315/112315-1/AASLD10.gif)
![AASLD11.gif](../images/112315/112315-1/AASLD11.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|